Evidence that genetic variation in 5-HT transporter expression is linked to changes in 5-HT2A receptor function

Neuropharmacology. 2008 Apr;54(5):776-83. doi: 10.1016/j.neuropharm.2007.12.001. Epub 2007 Dec 14.

Abstract

Variability in expression of the 5-HT transporter (5-HTT) gene in the human population has been associated with a range of behavioural phenotypes. The underlying mechanisms are unclear but may involve changes in 5-HT receptor levels and/or signalling. The present study used a novel 5-HTT overexpressing transgenic mouse to test the hypothesis that variability in 5-HTT expression may alter 5-HT(2A) receptor function. In wildtype mice, the 5-HT(2) receptor agonist DOI increased regional brain mRNA expression of two immediate early genes (c-fos and Arc), and induced head twitches, and both effects were abolished by pre-treatment with the 5-HT(2A) receptor antagonist MDL 100907. In 5-HTT overexpressing mice, DOI induced a greater increase in both c-fos and Arc mRNA expression in cortical brain regions, and more head twitches, compared to wildtype mice. Autoradiographic and in situ hybridisation experiments showed that 5-HT(2A) receptor binding sites and 5-HT(2A) receptor mRNA did not differ between transgenic and wildtype mice. Finally, the transgenic mice had lower regional brain 5-HT levels compared to wildtype mice. This depletion of 5-HT may underpin the increase in 5-HT(2A) receptor function because in wildtype mice 5-HT depletion using the 5-HT synthesis inhibitor, p-chlorophenylalanine, enhanced the head twitch response to DOI. These data demonstrate that elevated 5-HTT expression is accompanied by increased 5-HT(2A) receptor function, an effect possibly mediated by decreased availability of synaptic 5-HT. Variation in levels of 5-HTT expression may therefore be a source of variability in 5-HT(2A) receptor function, which may be an important modifier of 5-HTT-linked phenotypes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amphetamines / pharmacology
  • Analysis of Variance
  • Animals
  • Brain / drug effects
  • Brain / metabolism
  • Cytoskeletal Proteins / genetics
  • Cytoskeletal Proteins / metabolism
  • Dose-Response Relationship, Drug
  • Fluorobenzenes / pharmacology
  • Gene Expression / drug effects
  • Gene Expression / genetics*
  • Genetic Variation / physiology*
  • Head Movements / drug effects
  • Ketanserin / metabolism
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Nerve Tissue Proteins / genetics
  • Nerve Tissue Proteins / metabolism
  • Piperidines / pharmacology
  • Protein Binding / drug effects
  • Proto-Oncogene Proteins c-fos / genetics
  • Proto-Oncogene Proteins c-fos / metabolism
  • Receptor, Serotonin, 5-HT2A / physiology*
  • Serotonin / metabolism
  • Serotonin / pharmacology
  • Serotonin Antagonists / metabolism
  • Serotonin Antagonists / pharmacology
  • Serotonin Plasma Membrane Transport Proteins / genetics*
  • Serotonin Plasma Membrane Transport Proteins / metabolism*
  • Serotonin Receptor Agonists / pharmacology

Substances

  • Amphetamines
  • Cytoskeletal Proteins
  • Fluorobenzenes
  • Nerve Tissue Proteins
  • Piperidines
  • Proto-Oncogene Proteins c-fos
  • Receptor, Serotonin, 5-HT2A
  • Serotonin Antagonists
  • Serotonin Plasma Membrane Transport Proteins
  • Serotonin Receptor Agonists
  • activity regulated cytoskeletal-associated protein
  • Serotonin
  • Ketanserin
  • volinanserin
  • 4-iodo-2,5-dimethoxyphenylisopropylamine